Back

Predominance of a rare transthyretin mutation (p.Asp38Glu) in patients with hATTR cardiomyopathy: initial data from the Croatian Transthyretin Cardiac Amyloidosis Registry (CroATTR)

26 August 2023 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis: prevalence, genetics, and natural history Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Dubravka Sipus

University Hospital Centre Zagreb, Zagreb (Croatia)

8 More presentations in this session

Presentation thumbnail
Characterization and natural history of phenotypes in hereditary transthyretin amyloidosis
Doctor G. Saturi (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Imaging for prevalence assessment of cardiac transthyretin amyloidosis in patients > 60 years hospitalized in cardiology : the IMPACT study
Doctor E. Beard (Poitiers, FR)
Abstract Slides Video
Presentation thumbnail
Predictive Value of high-sensitivity cardiac troponin T in patients undergoing 99mTc pyrophosphate scintigraphy for suspected transthyretin amyloid cardiomyopathy
Doctor L. De Michieli (Padova, IT)
Abstract Slides Video
Presentation thumbnail
Prevalence of cardiac amyloidosis in patients undergoing carpal tunnel release with amyloid deposition in removed tenosynovium
Doctor S. Takashio (Kumamoto, JP)
Abstract Slides Video
Presentation thumbnail
Transtyretin cardiac amyloidosis in the elderly patient: always a wild type?
Doctor J. Costantino (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac amyloidosis: prevalence, genetics, and natural history

The Event

Event poster

ESC Congress 2023

26 August 2023 14:15 CET
You may be interested in
thumbnail
Congress Session
The evolving landscape of transthyretin amyloidosis
thumbnail
Congress Presentation
Neurological and cardiological profiling of patients with mutated transthyretin amyloidosis
thumbnail
Congress Presentation
Early symptoms and medical history of patients with transthyretin amyloidosis cardiomyopathy: Results from the multi-country OverTTuRe study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources